Zevra Therapeutics (ZVRA) Research & Development (2014 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Research & Development came in at $4.4 million in Q1 2026, up 34.81% YoY from $3.3 million in Q1 2025, and up 67.63% on a QoQ basis from $2.6 million in Q4 2025.
Zevra Therapeutics (ZVRA) Research & Development (2014 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 13 years of Research & Development data on file, last reported at $4.4 million in Q1 2026.
- Quarterly Research & Development rose 34.81% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.9 million (down 58.05% YoY) and the FY2025 annual result came in at $12.7 million, down 69.73% from the prior year.
- Research & Development grew to $4.4 million in Q1 2026, from $2.6 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $19.8 million in Q4 2022 to a low of $2.6 million in Q4 2025.
- A 5-year average of $7.8 million and a median of $7.4 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development surged 604.98% — and 2025, when it tumbled 73.46%.
- Tracing ZVRA's Research & Development over 5 years: stood at $19.8 million in 2022, then sank by 42.33% to $11.4 million in 2023, then declined by 26.87% to $8.4 million in 2024, then slumped by 68.63% to $2.6 million in 2025, then surged by 67.63% to $4.4 million in 2026.
- The last three Research & Development figures came in at $4.4 million (Q1 2026), $2.6 million (Q4 2025), and $3.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn | 4.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.49 Mn |
| Mar 31, 2026 | 4.39 Mn |
| Dec 31, 2025 | 2.62 Mn |
| Sep 30, 2025 | 3.43 Mn |
| Jun 30, 2025 | 3.43 Mn |
| Mar 31, 2025 | 3.26 Mn |
| Dec 31, 2024 | 8.35 Mn |
| Sep 30, 2024 | 10.95 Mn |
| Jun 30, 2024 | 10.52 Mn |
| Mar 31, 2024 | 12.28 Mn |
| Dec 31, 2023 | 11.42 Mn |
| Sep 30, 2023 | 12.30 Mn |
| Jun 30, 2023 | 7.43 Mn |
| Mar 31, 2023 | 8.66 Mn |
| Dec 31, 2022 | 19.80 Mn |
| Sep 30, 2022 | 5.39 Mn |
| Jun 30, 2022 | 4.80 Mn |
| Mar 31, 2022 | 3.08 Mn |
| Dec 31, 2021 | 2.81 Mn |
| Sep 30, 2021 | 2.24 Mn |